Z-endoxifen shows promise for breast cancer
Z-endoxifen, a potent derivative of the drug tamoxifen, could itself be a new treatment for the most common form of breast cancer...
List view / Grid view
Z-endoxifen, a potent derivative of the drug tamoxifen, could itself be a new treatment for the most common form of breast cancer...
Researchers have recently discovered an immunotherapy that uses existing cancer drugs in a whole new way...
Scientists have developed a method to efficiently modify natural antibodies that can deliver drugs to target cells...
Novartis announced that the European Commission approved ribociclib in combination with an aromatase inhibitor for treatment of postmenopausal women with metastatic breast cancer
A clinical trial to test a new cancer drug in patients with advanced solid tumours, launches in four centres across the UK...
Researchers have developed a new imaging technique to detect myeloid-derived suppressor cells’ accumulating in the lung...
A new deal on the breast cancer drug trastuzumab emtansine means that it can now be recommended for routine funding.
The Scottish Medicines Consortium (SMC) has made a final decision to turn down Perjeta (pertuzumab) for routine NHS funding for first line use in women whose HER2-positive breast cancer has returned to the breast but is inoperable, or where it has spread to other parts of the body.
Q BioMed Inc has initiated production of Strontium-89 Chloride, a radiopharmaceutical indicated for the analgesic treatment of metastatic breast and prostate cancer bone pain.
8 June 2017 | By Niamh Marriott, Junior Editor
AstraZeneca's positive results from its trial that showed a statistically-significant and clinically-meaningful improvement in progression-free survival...
7 June 2017 | By Niamh Marriott, Junior Editor
Data has shown similarity in efficacy and safety between CT-P6 (biosimilar trastuzumab candidate) and reference trastuzumab treatment in patients...
23 February 2017 | By Niamh Marriott, Digital Editor
AstraZeneca announced positive results from its Phase III trial comparing Lynparza to chemotherapy, to treat HER2-negative metastatic breast cancer...
3 February 2017 | By Niamh Marriott, Digital Editor
NICE has today published draft guidance which does not recommend Pfizer's breast cancer drug palbociclib for routine funding on the NHS...
Plants that have known medicinal properties are plentiful in Africa, and primary healthcare in the developing world has, since ancient times, relied heavily on their cultivation and use. Increasingly, too, the uses and effects of medicinal plants are becoming of interest globally.
3 November 2016 | By Niamh Louise Marriott, Digital Content Producer
NICE has said eribulin, which is also called Halaven and made by Eisai, should be an option for people with locally advanced or metastatic breast cancer...